DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new, single-infusion CAR-T cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T …
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
First human trial tests promising pill for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called SGR-1505 in adults with advanced B-cell cancers that have returned or stopped responding to previous treatments. The main goal is to find the highest safe dose and understand how the drug affects the body. Researchers…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test 'Ready-Made' immune cell therapy for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a new type of cancer treatment called P-CD19CD20-ALLO1 in adults with specific B-cell lymphomas that have come back or not responded to standard therapies. The treatment involves giving patients a single infusion of specially engine…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Personalized immune cells target Virus-Driven cancer in early trial
Disease control Recruiting nowThis early-phase study is testing a personalized cell therapy for patients with EBV-positive lymphoma that has returned or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack the Epstein-Barr virus (…
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphoma: trial tests promising drug combo
Disease control Recruiting nowThis study is testing whether adding an experimental drug called zilovertamab vedotin to standard chemotherapy works better than standard chemotherapy alone for adults whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to…
Matched conditions: DLBCL
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Blood test could help doctors personalize lymphoma care
Disease control Recruiting nowThis study is testing if a simple blood test can help doctors better manage early-stage lymphoma. It aims to see if tracking tiny bits of tumor DNA in the blood can predict treatment success and help decide which patients need radiation. The goal is to personalize therapy to cont…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat lymphoma: adding a pill to standard chemo
Disease control Recruiting nowThis study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists test new Two-Pronged attack on tough blood cancers
Disease control Recruiting nowThis is a small, early-stage study for adults with B-cell leukemia or lymphoma that has come back or not responded to other treatments. The goal is to test the safety of a new two-step approach. First, patients receive a targeted radioactive drug (131-I apamistamab), followed by …
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC
-
Landmark study seeks better paths for lymphoma patients too frail for standard care
Knowledge-focused Recruiting nowThis study aims to collect real-world information on how doctors treat patients with large B-cell lymphoma who are too frail for standard, full-dose chemotherapy or whose cancer has returned after initial treatment. By gathering data and samples from 800 patients, researchers hop…
Matched conditions: DLBCL
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC